PetMed Express (PETS) Stock Price, News & Analysis

Company Overview

PetMed Express, Inc. operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications. The company launched its initial public offering in 2000 and has since developed an in‐house team of veterinarians and pharmacy professionals to review prescriptions and provide customer support. With a multi‐channel approach that includes online ordering, telephone service and direct mail catalogs, PetMed Express seeks to simplify the process of obtaining essential pet health products.

PetMed Express primarily serves customers across the United States, with select offerings available in Canada. Its operations center around a fulfillment facility in Florida, supported by a network of third‐party carriers for nationwide delivery. The company is led by its founder and Chief Executive Officer, Marc Puleo, who oversees strategy and business development alongside a management team experienced in pharmaceutical distribution and e-commerce. PetMed Express continues to focus on expanding its product portfolio, enhancing digital capabilities and maintaining compliance with regulatory standards in veterinary pharmacy.

Key Stats

• Today's Range: $2.46 to $2.65
• 50-Day Range: $2.42 to $3.21
• 52-Week Range: $2.42 to $6.85
• Volume: 110,301 shs
• Average Volume: 91,136 shs
• Market Capitalization: $55.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.20
• Consensus Rating: Sell

PetMed Express Stock Analysis - MarketRank™

PetMed Express scored higher than 39% of companies evaluated by MarketBeat, and ranked 155th out of 214 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Sell

Consensus Rating

PetMed Express has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

PetMed Express has a consensus price target of $3.20, representing about 21.2% upside from its current price of $2.64.

Amount of Analyst Coverage

PetMed Express has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -84.21%

Earnings Growth

Earnings for PetMed Express are expected to decrease by -84.21% in the coming year, from $0.19 to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PetMed Express is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PetMed Express is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PetMed Express has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.64% of the float of PetMed Express has been sold short.

Short Interest Ratio / Days to Cover

PetMed Express has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.

Change versus previous month

Short interest in PetMed Express has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

PetMed Express does not currently pay a dividend.

Dividend Growth

PetMed Express does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of PetMed Express is 9,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on EPS estimates, PetMed Express will have a dividend payout ratio of 3,000.00% in the coming year. This indicates that PetMed Express may not be able to sustain their current dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.64% of the float of PetMed Express has been sold short.

Short Interest Ratio / Days to Cover

PetMed Express has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.

Change versus previous month

Short interest in PetMed Express has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

PetMed Express has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Retail/Wholesale companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for PetMed Express this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for PETS on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, PetMed Express insiders have bought more of their company's stock than they have sold. Specifically, they have bought $699,592.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.10% of the stock of PetMed Express is held by insiders.

Percentage Held by Institutions

73.33% of the stock of PetMed Express is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PETS Stock Analysis - Frequently Asked Questions

How have PETS shares performed this year?

PetMed Express' stock was trading at $4.82 on January 1st, 2025. Since then, PETS stock has decreased by 45.2% and is now trading at $2.64.

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) posted its quarterly earnings results on Tuesday, October, 14th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.60. The firm had revenue of $46.47 million for the quarter. PetMed Express had a negative trailing twelve-month return on equity of 6.76% and a negative net margin of 2.76%.

How do I buy shares of PetMed Express?

Shares of PETS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PetMed Express investors own include Meta Platforms (META), NVIDIA (NVDA), Intel (INTC), Pfizer (PFE), Walt Disney (DIS), Ford Motor (F) and PayPal (PYPL).

Company Calendar

• Last Earnings: 10/14/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Retail/Wholesale
• Industry: INTERNET COMMERCE
• Sub-Industry: Internet Retail
• Current Symbol: NASDAQ:PETS
• CIK: 1040130
• Web: www.1800petmeds.com
• Phone: (561) 526-4444
• Fax: 561-526-4445
• Employees: 210
• Year Founded: 1996

Price Target and Rating

• Average Price Target for PetMed Express: $3.20
• High Price Target: $3.20
• Low Price Target: $3.20
• Potential Upside/Downside: +22.1%
• Consensus Rating: Sell
• Rating Score (0-4): 1.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.79
• P/E Growth: N/A
• Net Income: -$6.27 million
• Net Margins: -2.76%
• Pretax Margin: -0.26%
• Return on Equity: -6.76%
• Return on Assets: -4.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.26
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $226.97 million
• Price / Sales: 0.24
• Cash Flow: $0.04 per share
• Price / Cash Flow: 67.51
• Book Value: $4.12 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 21,016,000
• Free Float: 20,785,000
• Market Cap: $55.06 million
• Optionable: Optionable
• Beta: 0.73